De-Risking In Vivo CAR-T Development

​Join us for an in-depth Lunch & Learn exploring a comprehensive approach to de‑risking in vivo CAR‑T development.

​This session will highlight a fully integrated Lentiviral Vector (LVV) and mRNA–tLNP platform capabilities. The session will spotlight a global IIT strategy, that enables developers to accelerate early clinical insights, reduce cost, and streamline the IND pathway.

​Attendees will gain actionable insights into de‑risking program development, selecting optimal modality‑specific manufacturing routes, and understanding how integrated CMC and regulatory strategies can shorten timelines from concept to clinic.